Descrizione

Risk of bias summary for included randomized controlled trials of curcumin in ulcerative colitis evaluates each study across Cochrane risk domains. Most studies showed low risk for blinding and outcome reporting.

Figure 7

Chart

Source Paper

Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients (2018)

PMID: 30424514

DOI: 10.3390/nu10111737

Cite This Figure

![Figure 7: Risk of bias summary for included randomized controlled trials of curcumin in ulcerative colitis evaluates each study across Cochrane risk domains. Most studies showed low risk for blinding and outcome reporting.]()

> Source: Maria G Grammatikopoulou et al. "Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Co." *Nutrients*, 2018. PMID: [30424514](https://pubmed.ncbi.nlm.nih.gov/30424514/)

<figure>
  <img src="" alt="Risk of bias summary for included randomized controlled trials of curcumin in ulcerative colitis evaluates each study across Cochrane risk domains. Most studies showed low risk for blinding and outcome reporting." />
  <figcaption>Figure 7. Risk of bias summary for included randomized controlled trials of curcumin in ulcerative colitis evaluates each study across Cochrane risk domains. Most studies showed low risk for blinding and outcome reporting.<br>  Source: Maria G Grammatikopoulou et al. "Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Co." <em>Nutrients</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30424514/">30424514</a></figcaption>
</figure>

Evidenze correlate

Curcumin per Ulcerative Colitis (UC)

Grado B · 5 studi